Nintedanib Newbury

Nintedanib, the active ingredient in Nintedanib Newbury, is a tyrosine kinase inhibitor presented as a tablet for oral use. It is indicated for the treatment of idiopathic pulmonary fibrosis and systemic sclerosis‑associated interstitial lung disease in adult patients.

GNH USA supplies Nintedanib Newbury as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Nintedanib is an antifibrotic agent used in specific interstitial lung disease pathways.

Idiopathic pulmonary fibrosis: slows disease progression and preserves lung function. Systemic sclerosis‑associated interstitial lung disease: reduces decline in forced vital capacity and improves quality of life.

Nintedanib may cause a range of adverse reactions that vary in frequency and severity.

Common Side Effects: - Diarrhea: frequent, watery stools often requiring supportive care. - Nausea and vomiting: mild to moderate, may improve with food intake. - Abdominal pain: crampy discomfort in the upper abdomen. - Decreased appetite: reduced desire to eat, potentially leading to weight loss.

Serious or Rare Side Effects: - Elevated liver enzymes: may indicate hepatic injury; monitor transaminases. - Severe bleeding: gastrointestinal or other hemorrhagic events. - Arterial thromboembolism: rare clot formation in arteries, requiring urgent evaluation.

Before initiating therapy, clinicians should assess baseline organ function and risk factors. - Liver function monitoring: obtain baseline and periodic ALT/AST levels. - Cardiovascular assessment: evaluate for history of ischemic heart disease or uncontrolled hypertension. - Bleeding risk: avoid concomitant use with strong anticoagulants unless medically necessary. - Pregnancy and lactation: use is not recommended; benefits must outweigh potential risks. - Store at below 25°C: keep in the original packaging, protect from moisture and direct sunlight.

Nintedanib interacts with several drug classes that can alter its exposure or safety profile.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole): may increase plasma concentrations. - Potent P‑gp inhibitors (e.g., clarithromycin): can raise exposure levels. - Anticoagulants (e.g., warfarin) combined with high bleeding risk agents: may potentiate hemorrhage.

Moderate Interactions (Monitor Closely): - CYP3A4 inducers (e.g., rifampicin, carbamazepine): may reduce therapeutic effect. - Moderate CYP3A4 inhibitors (e.g., erythromycin, fluconazole): require dose adjustment or close monitoring. - Antacids or proton‑pump inhibitors: may affect absorption; separate administration times if needed.